玩股撇步(動畫小學堂)  

  • 理想的成長型公司, 本業EPS的成長幅度會大於營收的成長幅度
  • 營收到某個數字後, 本業EPS呈現不成比例的增加, 有可能是規模經濟的效應
  • 如果是有淡旺季的公司, 是否有淡季不淡, 旺季更旺的情況
  • 漲很多的股票要留意 EPS 較上季是否有大幅衰退的情況
  • 如果EPS衰退,要觀察同業是不是有一樣的狀況
  • 要留意增資減資和公司債對股本及EPS的影響
成長能力-近8季
加權平均股數 QoQ YoYEPS QoQ YoY本業EPS QoQ YoY累計EPS QoQ YoY營收 QoQ YoY毛利率(%) QoQ YoY營業利益率 QoQ YoY稅後淨利率 QoQ YoY營業利益 QoQ YoY稅後淨利 QoQ YoY稅前淨利率(%) QoQ YoY稅後淨利率(%) QoQ YoY兩季平均(YOY)營收成長率(%)兩季平均(YOY)EPS成長率(%)兩季平均(YOY)本業EPS成長率(%)
26Q1 (8)1390.00.0-0.3854.76-151.35-0.3652.63-152.94-0.3851.28-151.352.61-20.18-47.752.75-7.0-25.82-25.5947.32-230.63-28.3158.65-245.7-0.6757.86-168.37-0.5354.7-151.96-26.8048.81-228.05-28.3158.65-245.7-18.80-25.06-59.40
25Q4 (7)1390.00.0-0.84-104.88-2.44-0.76-171.4319.15-0.78-1400.046.943.27-17.42-1.2156.7237.3715.26-48.58-408.16-201.93-68.47-329.01-91.2-1.59-318.42-200.0-1.17-108.93-2.63-52.35-275.54-370.35-68.47-329.01-91.2-3.86-78.36-1535.71
25Q3 (6)1390.00.0-0.41-51.85-115.79-0.28-2900.0-115.380.06-86.96109.233.969.7-9.3841.29-25.99-21.71-9.5640.84-1391.89-15.9645.75-419.87-0.3834.48-1366.67-0.56-47.37-107.41-13.9448.14-940.3-15.9645.75-419.87-8.98-94.17-1499.27
25Q2 (5)1390.00.0-0.27-136.49-400.00.01-98.53102.270.46-37.84200.03.61-27.661.9855.79-21.54-11.28-16.16-182.49-105.6-29.42-251.42-401.43-0.58-159.18-107.14-0.38-137.25-416.67-26.88-228.43-310.82-29.42-251.42-401.43--0.00
25Q1 (4)1390.00.00.74190.240.00.68172.340.00.74150.340.04.9950.760.071.1144.50.019.59221.750.019.43154.260.00.98284.910.01.02189.470.020.93288.050.019.43154.260.0--0.00
24Q4 (3)1390.00.0-0.82-331.580.0-0.94-623.080.0-1.47-126.150.03.31-24.260.049.21-6.690.0-16.09-2274.320.0-35.81-1066.450.0-0.53-1866.670.0-1.14-322.220.0-11.13-730.60.0-35.81-1066.450.0--0.00
24Q3 (2)1390.00.0-0.19-311.110.0-0.1370.450.0-0.65-41.30.04.3723.450.052.74-16.130.00.74109.410.0-3.07-131.450.00.03110.710.0-0.27-325.00.0-1.34-110.510.0-3.07-131.450.0--0.00
24Q2 (1)1390.00.00.090.00.0-0.440.00.0-0.460.00.03.540.00.062.880.00.0-7.860.00.09.760.00.0-0.280.00.00.120.00.012.750.00.09.760.00.0--0.00
年/月營收月增率(%)去年同期年增率(%)累計營收累計營收年增率(%)近三月累計營收存貨銷售比自結稅前EPS自結稅前累計EPS備註(年增率變動50%需說明原因)
2026/40.94-6.07-10.293.56-41.132.63N/A-
2026/31.048.37-67.92.62-47.632.622.49.
2026/20.68-27.43-24.01.61-13.582.562.55-
2026/10.93-1.27-4.040.93-4.042.782.35-
2025/120.954.99-11.0515.8315.283.271.78-
2025/110.9-36.66-17.214.8817.494.031.44-
2025/101.42-16.6622.8813.9820.754.231.37-
2025/91.7154.09-14.3812.5620.513.971.67-
2025/81.11-4.07-2.810.8528.763.621.84-
2025/71.15-14.85-6.599.7533.693.71.79.
2025/61.3613.7721.838.5941.913.61.93-
2025/51.1913.21-16.187.2446.435.371.29,
2025/41.05-66.394.396.0571.715.071.37.
2025/33.13251.3202.954.9998.74.991.35完成資產交易及技術授權所致
2025/20.89-8.3727.91.8625.922.932.31-
2025/10.97-8.4924.150.9724.153.122.16-
2024/121.06-2.2521.7313.7318.573.311.95-
2024/111.09-5.99-14.6512.6618.314.241.52-
2024/101.16-41.94-26.0111.5822.764.291.5.
2024/91.9974.9510.7710.4232.464.371.42-
2024/81.14-7.82-31.568.4338.883.491.78-
2024/71.2411.0674.867.2965.493.771.64.
2024/61.11-21.7241.866.0563.73.541.8.
2024/51.4241.093.244.9469.583.461.85.
2024/41.01-2.4689.363.5261.62.742.33.
2024/31.0348.3292.922.5152.632.51N/A.
2024/20.7-11.0735.361.4833.22.34N/A.
2024/10.78-9.3231.340.7831.342.92N/A-
2023/120.86-32.1832.2411.579.553.7N/A.
2023/111.27-18.576.2610.78.054.64N/A.
2023/101.56-13.07136.489.432.685.03N/A.
2023/91.88.08166.777.87-7.694.17N/A.
2023/81.66135.5232.426.07-22.673.15N/A.
2023/70.71-9.8930.754.4-40.052.23N/A.
2023/60.786.62-2.433.7-45.672.05N/A.
2023/50.7438.1819.392.91-51.461.8N/A.
2023/40.53-0.63-1.592.18-59.561.58N/A.
2023/30.544.06-66.851.65-66.031.65N/A.
2023/20.51-13.79.941.11-65.611.76N/A.
2023/10.6-8.7-78.410.6-78.411.97N/A.
2022/120.65-9.61-81.2910.56-73.072.04N/A.
2022/110.729.33-93.969.91-72.272.06N/A.
2022/100.66-1.93-89.499.18-61.331.84N/A.
2022/90.6734.68-88.478.52-51.191.71N/A.
2022/80.5-7.36-93.477.85-32.421.84N/A.
2022/70.54-32.7661.057.3586.451.96N/A.
2022/60.830.4848.866.8188.821.96N/A.
2022/50.6213.888.596.095.852.77N/A.
2022/40.54-66.53-15.725.39115.662.62N/A.
2022/31.62245.24119.884.85161.084.85N/A新冠肺炎疫苗自110年8月開始銷售
2022/20.47-83.06-12.783.23188.076.72N/A新冠肺炎疫苗自110年8月開始銷售
2022/12.76-20.88372.352.76372.3518.23N/A新冠肺炎疫苗自110年8月開始銷售
2021/123.49-70.82360.8239.22537.1321.76N/A新冠肺炎疫苗自110年8月開始持續銷售
2021/1111.9790.311928.7235.73561.8924.11N/A新冠肺炎疫苗自110年8月開始持續銷售
2021/106.297.571037.3723.75394.0919.81N/A新冠肺炎疫苗自110年8月開始持續銷售
2021/95.85-23.78838.7217.46310.4513.86N/A新冠肺炎疫苗自110年8月開始持續銷售
2021/87.672187.121717.8311.61219.838.55N/A主要係因新冠肺炎疫苗開始銷售所致
2021/70.34-37.85-32.283.9422.791.44N/A-
2021/60.54-4.816.213.6132.70.0N/A-
2021/50.57-11.6283.083.0738.80.0N/A主要係藥品代工收入增加所致。
成長能力-近5年
加權平均股數 YoYEPS YoY本業EPS YoY營收 YoY毛利率(%) YoY營業利益率 YoY稅後淨利率 YoY營業利益 YoY稅前淨利 YoY稅後淨利 YoY
2025 (5)1390.0-0.780-0.34015.8315.2957.194.15-9.920-18.700-1.570-2.190-1.090
2024 (4)1390.0-1.470-2.22013.7318.5754.912.98-15.820-16.200-2.170-1.130-2.050
2023 (3)1390.0-4.030-3.71011.589.6653.32543.96-106.510-126.980-12.330-12.790-5.610
2022 (2)1390.0-4.860-3.38010.56-73.078.28-87.27-157.870-182.920-16.670-18.730-6.760
2021 (1)1390.0-0.380-2.88039.22536.6965.05020.12027.3007.89011.360-0.530

財務分析相關資訊

免責聲明

本網站所有資料僅供參考,如使用者依本資料交易發生交易損失需自行負責,本網站對資料內容錯誤﹑更新延誤不負任何責任。